Vireo Growth (VREOF) Total Debt Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) Total Debt Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 15.43% |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -7.08% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 11.33% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -3.67% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -10.43% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -13.72% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 92.83% |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | 72.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.55% |
| Dec 31, 2025 | 35.35% |
| Sep 30, 2025 | 38.34% |
| Jun 30, 2025 | 33.34% |
| Mar 31, 2025 | 26.11% |
| Dec 31, 2024 | 32.24% |
| Sep 30, 2024 | 38.91% |
| Jun 30, 2024 | 47.18% |
| Mar 31, 2024 | 48.07% |
| Dec 31, 2023 | 278.57% |